Our data showed that the specimens obtained by TBNA of peripheral lesions provided adequate material for full molecular profile of the tumor for current therapies (including PD-L1 expression) in 86.6% of patients with non-small cell lung cancer. The gene discussed is CD274; the disease is neoplasm.